Project Grant R01HL175060
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$674K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $511,135 to the University of California, Los Angeles (UCLA) for research on the structure and biology of Tissue Factor Pathway Inhibitor-2 (TFPI-2). The key objectives of this award are to: 1) delineate the specific residues and segments of the TFPI-2 Kunitz Domain 1 (KD1) that confer protease specificity for plasmin, Factor XIa, and...
This $151,523 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research by The Medical College of Wisconsin, Inc. to investigate the role of the protein fibrinogen in regulating inflammatory and clotting processes associated with acute and chronic venous thrombosis (blood clots). The research will utilize novel RNA therapy delivered via lipid nanoparticles to selectively reduce...
This federal Project Grant award of $395,314 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to define the innate immune cell profile and cytokine microenvironment that mediate the development of inhibitory antibodies against factor VIII in individuals with hemophilia A. The research aims to 1) examine the cytokine profile and activation of conventional dendritic cells (CDC2) that drive CD4+ T cell...
The $1,371,242 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a comprehensive study to identify genetic, environmental, and immunological factors underlying the high incidence of Factor VIII inhibitor development in hemophilia A patients of Mexican ancestry. The 4-year project aims to: 1) enroll and extensively characterize a cohort of 200 severe hemophilia A patients of Mexican...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to characterize the role of Factor XII (FXII) in the thrombo-inflammatory complications of sickle cell disease (SCD). The $1,449,454 award to the University of North Carolina at Chapel Hill (UNC-CH) will fund research to: 1) identify disease-specific triggers of FXII activation, 2) characterize FXII effects on neutrophil...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $685,884 to the University of North Carolina at Chapel Hill to conduct research on the regulation of coagulation and thrombosis by C1 inhibitor. The research aims to elucidate the molecular mechanisms by which endogenous C1 inhibitor regulates coagulation and venous thrombosis, evaluate the impact of C1 inhibitor deficiency on coagulation...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports innovative research on the use of short inhibitory RNAs (siRNAs) to modulate gene expression in megakaryocytes and platelets. The $552,413 award to Thomas Jefferson University, doing business as Sidney Kimmel Medical College, has an ultimate completion date of January 31, 2029. The key research objectives are: 1) investigating the use of siRNA-mediated...
This $827,665 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of scalable methods to identify causal genetic variants, relevant cell types, and target genes underlying cardiovascular disease (CVD). The grantee, New York Genome Center, Inc. (NYGC), will leverage multi-ancestry genome-wide association studies (GWAS) and apply innovative techniques like CRISPR screens,...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $295,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Hematherix LLC, a woman-owned small business in California. The award supports the development of SuperFVa, an engineered variant of activated coagulation cofactor Factor V, as a targeted therapy to prevent and correct acute traumatic coagulopathy (ATC). ATC is characterized by diminished levels of key clotting factors, leading to...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to define the role of platelet ABO(H) blood group antigens in hemostasis (blood clotting) and thrombosis (blood clotting disorders). The $445,708 award to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System Incorporated, will fund research with the following objectives: Determine the impact of ABO(H) glycans on...